Kane Biotech Stock Fundamentals
| KNBIF Stock | USD 0.08 0.0003 0.39% |
Kane Biotech fundamentals help investors to digest information that contributes to Kane Biotech's financial success or failures. It also enables traders to predict the movement of Kane OTC Stock. The fundamental analysis module provides a way to measure Kane Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kane Biotech otc stock.
Kane |
Kane Biotech OTC Stock Return On Asset Analysis
Kane Biotech's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Kane Biotech Return On Asset | -0.39 |
Most of Kane Biotech's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kane Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Kane Biotech has a Return On Asset of -0.3915. This is 95.53% lower than that of the Healthcare sector and 98.34% lower than that of the Biotechnology industry. The return on asset for all United States stocks is 179.64% higher than that of the company.
Kane Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kane Biotech's current stock value. Our valuation model uses many indicators to compare Kane Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kane Biotech competition to find correlations between indicators driving Kane Biotech's intrinsic value. More Info.Kane Biotech is rated second overall in return on equity category among its peers. It is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kane Biotech's earnings, one of the primary drivers of an investment's value.Kane Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kane Biotech's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Kane Biotech could also be used in its relative valuation, which is a method of valuing Kane Biotech by comparing valuation metrics of similar companies.Kane Biotech is currently under evaluation in return on asset category among its peers.
Kane Fundamentals
| Return On Equity | -5.97 | |||
| Return On Asset | -0.39 | |||
| Profit Margin | (1.80) % | |||
| Operating Margin | (1.72) % | |||
| Current Valuation | 12.47 M | |||
| Shares Outstanding | 124.83 M | |||
| Shares Owned By Insiders | 26.82 % | |||
| Price To Earning | 4.68 X | |||
| Price To Book | 102.61 X | |||
| Price To Sales | 3.45 X | |||
| Revenue | 1.61 M | |||
| Gross Profit | 568.44 K | |||
| EBITDA | (4.25 M) | |||
| Net Income | (4.6 M) | |||
| Cash And Equivalents | 2.53 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 1.12 M | |||
| Debt To Equity | 7.12 % | |||
| Current Ratio | 0.67 X | |||
| Book Value Per Share | (0.05) X | |||
| Cash Flow From Operations | (2.29 M) | |||
| Earnings Per Share | (0.03) X | |||
| Number Of Employees | 18 | |||
| Beta | 0.19 | |||
| Market Capitalization | 10.45 M | |||
| Total Asset | 6.13 M | |||
| Z Score | 5.4 | |||
| Net Asset | 6.13 M |
About Kane Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kane Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kane Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kane Biotech based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada. Kane Biotech is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Kane OTC Stock
Kane Biotech financial ratios help investors to determine whether Kane OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kane with respect to the benefits of owning Kane Biotech security.